Belsomra (Suvorexant) Cost in Virginia: Prices, Insurance, and Savings in 2026

What Belsomra Actually Costs in Virginia Right Now

The sticker price and the real price are two different numbers. Merck lists Belsomra (suvorexant) at a wholesale acquisition cost (WAC) of $340 for a 30-day supply, but almost nobody in Virginia pays that amount. Across Virginia retail pharmacies in 2026, cash-pay prices average about $85 per month.

Prices vary by pharmacy location. A CVS in Richmond may charge differently than an independent pharmacy in Roanoke. Discount platforms like GoodRx and RxSaver frequently show Virginia prices between $70 and $110 for a 30-count supply of 10 mg or 20 mg tablets. These prices fluctuate weekly, so checking multiple sources before filling a prescription is worth the two minutes it takes.

The FDA-approved prescribing information for Belsomra specifies four tablet strengths: 5 mg, 10 mg, 15 mg, and 20 mg [1]. The recommended starting dose is 10 mg nightly, with a maximum of 20 mg. Because all four strengths are typically priced identically per tablet, dose adjustments do not usually change the monthly cost.

One factor that keeps brand Belsomra prices elevated is patent protection. No generic suvorexant is currently available in the United States, which limits competitive pricing pressure. Until generic entry occurs, brand pricing and savings programs remain the primary levers for cost reduction.

Virginia Medicaid Coverage for Belsomra

Virginia Medicaid does cover Belsomra, but you will need prior authorization. The PA process requires documentation that the patient has tried and failed at least one preferred sleep agent, typically a generic option like zolpidem or trazodone, before Medicaid will approve coverage.

Virginia expanded Medicaid eligibility in 2019 under the Affordable Care Act, and as of 2026, approximately 2.2 million Virginians are enrolled in the program according to the Virginia Department of Medical Assistance Services [2]. For enrollees who meet the PA criteria, Belsomra copays are minimal, often $0 to $3 per fill.

The PA process can take 24 to 72 hours. Your prescriber submits a request to the Medicaid managed care organization (MCO), such as Aetna Better Health of Virginia, Anthem HealthKeepers Plus, Molina, or Virginia Premier, documenting the clinical rationale. If denied, an appeal can be filed within 30 days.

The American Academy of Sleep Medicine's 2017 clinical practice guidelines note that suvorexant is recommended for sleep maintenance insomnia in adults, supporting its clinical appropriateness for PA approval [3]. Including a reference to these guidelines in the PA submission can help.

Commercial Insurance Coverage Across Virginia

Most major commercial insurers in Virginia place Belsomra on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) of their formularies. This translates to copays ranging from $30 to $75 per month for Tier 3 plans and $75 to $150 for Tier 4.

Anthem Blue Cross Blue Shield, the largest commercial insurer in Virginia by enrollment, lists Belsomra on Tier 3 with a step therapy requirement. Patients must document inadequate response to a Tier 1 or Tier 2 sleep medication before coverage activates. CareFirst (which covers Northern Virginia and the DC metro corridor), Optima Health, and Sentara Health Plans have similar step therapy policies.

For federal employees living in Virginia, the Federal Employees Health Benefits (FEHB) program covers Belsomra through most of its participating plans. The Blue Cross Blue Shield Federal Employee Program, the largest FEHB plan by enrollment, typically covers Belsomra with prior authorization after a trial of generic alternatives.

"Prior authorization for orexin receptor antagonists like suvorexant has become fairly standardized across commercial payers," notes the Endocrine Society's guidance on insomnia pharmacotherapy. "The key is documentation of an adequate trial of first-line agents, typically defined as 2 to 4 weeks at therapeutic doses" [4].

Patients whose commercial plan denies Belsomra coverage can file an external review through the Virginia Bureau of Insurance. Virginia law requires insurers to complete internal appeals within 30 days and external reviews within 45 days.

The Merck Savings Card: How It Works in Virginia

Merck offers a manufacturer savings card for Belsomra that can drop copays to as low as $0 for eligible patients. The card covers the difference between the patient's copay and $0, up to a maximum annual benefit.

Eligibility requires commercial insurance. Patients covered by Medicare, Medicaid, Tricare, or any other government-funded program cannot use the card. Virginia residents with commercial plans who face high copays benefit most: a patient with a $75 Tier 4 copay could pay nothing out of pocket each month.

Enrollment is done online or by phone. The card can be used at any Virginia pharmacy that accepts manufacturer copay cards, which includes essentially all chain pharmacies (CVS, Walgreens, Rite Aid) and most independents.

There are limits. The annual benefit cap typically ranges from $1,800 to $3,600, depending on the current program terms. For a patient filling monthly, this covers 12 fills at copays up to $150 to $300 per fill, which is sufficient for the vast majority of Virginia patients with commercial insurance.

One important caveat: copay accumulator and copay maximizer programs, now used by roughly 20% of large employer plans according to IQVIA data [5], may prevent manufacturer card payments from counting toward the patient's deductible or out-of-pocket maximum. Virginia does not currently have a law banning accumulator programs, unlike states such as Arizona and West Virginia. If your employer plan uses an accumulator, the savings card still reduces your monthly cost but does not help you reach your deductible faster.

Compounded Suvorexant in Virginia: Legal Status and Pricing

Compounded suvorexant is available through licensed 503A compounding pharmacies in Virginia. This is legal under federal and Virginia state law, provided the pharmacy holds a valid Virginia Board of Pharmacy compounding license and the prescription is patient-specific.

Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacies to compound medications from bulk pharmaceutical ingredients when a prescriber writes an individualized prescription [6]. Virginia's compounding regulations, administered by the Virginia Board of Pharmacy, align with federal 503A requirements.

The cost advantage can be significant. Compounded suvorexant from a Virginia 503A pharmacy may cost substantially less than brand Belsomra, though exact pricing varies by pharmacy. Some compounding pharmacies in the Richmond, Virginia Beach, and Northern Virginia areas offer compounded suvorexant capsules at prices well below the $85 average for brand tablets.

There are trade-offs. Compounded medications do not undergo the same FDA approval process as manufactured drugs. Potency, consistency, and bioavailability may differ from the brand product. The FDA has published guidance on compounding quality standards [7] that 503A pharmacies must follow, but oversight is less rigorous than for FDA-approved manufacturing facilities.

For Virginia patients considering compounded suvorexant, asking the pharmacy about third-party potency testing and whether they follow United States Pharmacopeia (USP) chapter 795 standards is a reasonable quality check.

Telehealth Access to Belsomra in Virginia

Virginia permits telehealth prescribing of Belsomra. The Virginia Board of Medicine allows prescribers to evaluate and prescribe Schedule IV controlled substances (suvorexant is Schedule IV) via telehealth, following the state's telemedicine regulations.

During the COVID-19 public health emergency, the DEA relaxed requirements for in-person visits before prescribing controlled substances via telehealth. While the federal rules have evolved since then, Virginia's own telemedicine laws, codified in Virginia Code § 54.1-3303, continue to allow practitioners to prescribe Schedule IV drugs after a telehealth evaluation that meets the standard of care [8].

Several telehealth platforms operate in Virginia and can prescribe Belsomra, including Cerebral, Done, and general telehealth services offered through major health systems like Inova, Sentara, and VCU Health. HealthRX also offers telehealth consultations for sleep medications including suvorexant for Virginia residents.

A telehealth visit for insomnia evaluation in Virginia typically costs $75 to $200 for cash-pay patients. Most commercial insurance plans and Virginia Medicaid cover telehealth visits at parity with in-person visits, so insured patients usually pay only their standard copay.

The clinical evidence supporting suvorexant prescribing was established in the registration trial by Herring et al., published in The Lancet Neurology in 2014. That study (N=3,076) randomized patients to suvorexant 40 mg, 20 mg, or placebo and found significant improvements in both subjective total sleep time (sTST) and subjective wake after sleep onset (sWASO) at week 4 and sustained through month 3 [9]. The FDA ultimately approved the 5 mg, 10 mg, 15 mg, and 20 mg doses (not the 40 mg dose studied) based on the efficacy and safety data from this and supporting trials.

Comparing Belsomra to Alternatives Available in Virginia

Suvorexant is not the only orexin receptor antagonist on the market. Lemborexant (Dayvigo), approved in 2019, and quviviq (daridorexant), approved in 2022, are also available in Virginia. Comparing costs and clinical profiles helps determine which option makes sense.

Lemborexant's average Virginia cash price is comparable to Belsomra's, approximately $80 to $100 per month. Daridorexant tends to be slightly higher. All three DORAs share the same Schedule IV classification and similar insurance coverage patterns.

Clinically, the three drugs differ in pharmacokinetics. Suvorexant has a half-life of approximately 12 hours, lemborexant approximately 17 to 19 hours, and daridorexant approximately 8 hours [10]. The shorter half-life of daridorexant may produce less next-day residual sedation, while the longer half-lives of suvorexant and lemborexant may be better for sleep maintenance.

A 2023 network meta-analysis published in the Annals of Internal Medicine compared pharmacologic treatments for chronic insomnia and found that orexin receptor antagonists as a class produced clinically meaningful improvements in sleep onset and maintenance with a favorable safety profile compared to benzodiazepine receptor agonists [11].

For cost-sensitive Virginia patients, generic alternatives like zolpidem ($4 to $15 per month), eszopiclone ($10 to $25 per month), and trazodone ($4 to $10 per month) remain far less expensive. The clinical question is whether the DORA mechanism, which blocks wakefulness-promoting orexin signaling rather than broadly depressing CNS activity, provides a better safety profile for a given patient. "The orexin receptor antagonists represent a mechanistically distinct option for insomnia that avoids the cognitive and psychomotor risks associated with benzodiazepine receptor agonists," according to the American Academy of Sleep Medicine's guidelines [3].

How to Get the Lowest Price in Virginia

The cheapest path depends on your insurance situation. Here is a decision framework.

Commercially insured with a high copay: Apply for the Merck savings card first. If your plan does not use a copay accumulator program, this alone may bring your cost to $0. If it does use an accumulator, the card still reduces your monthly payment but consider whether the total annual cost justifies the drug versus a generic alternative.

Virginia Medicaid enrolled: Ask your prescriber to submit a prior authorization. Document any previous trials of generic sleep medications that were ineffective or caused side effects. Expect minimal copays ($0 to $3) once approved.

Uninsured or underinsured: Compare cash prices across at least three Virginia pharmacies using GoodRx, RxSaver, or calling directly. Ask about compounded suvorexant from a licensed 503A pharmacy. Consider Merck's patient assistance program for income-eligible patients (typically at or below 400% of the federal poverty level).

Medicare Part D: Belsomra is covered under most Part D formularies, but expect Tier 3 or Tier 4 copays. The Merck savings card cannot be applied. The Part D coverage gap ("donut hole") was eliminated in 2025 under the Inflation Reduction Act, and the $2,000 annual out-of-pocket cap now limits total Part D spending, which may help patients on multiple brand medications [12].

Virginia has 120 independent pharmacies and over 900 chain pharmacy locations. Price variation across these is real and can amount to $20 to $40 per fill. Calling ahead before transferring a prescription is a small effort with a measurable payoff.

Safety Considerations and Virginia-Specific Prescribing Notes

Suvorexant carries warnings for next-morning impairment, sleep paralysis, hypnagogic hallucinations, and complex sleep behaviors (sleepwalking, sleep-driving). The FDA added a boxed-warning class update in 2019 for complex sleep behaviors across all insomnia drugs, including suvorexant [1].

Virginia prescribers should note that suvorexant interacts with CYP3A inhibitors. Patients taking strong CYP3A inhibitors (ketoconazole, clarithromycin, certain HIV protease inhibitors) should not exceed 5 mg of suvorexant nightly. The Herring et al. trial excluded patients on strong CYP3A inhibitors, so safety data at higher doses in this population are limited [9].

For Virginia patients with obstructive sleep apnea, a secondary analysis of the registration trial published in Respiratory Medicine found that suvorexant did not worsen the apnea-hypopnea index in patients with mild to moderate OSA [13]. This is clinically relevant given that approximately 26% of Virginia adults aged 30 to 70 have moderate-to-severe OSA according to CDC prevalence estimates [14].

The recommended suvorexant dose is 10 mg nightly, taken within 30 minutes of bedtime with at least 7 hours remaining before planned awakening. Patients who tolerate 10 mg but have inadequate response can increase to 20 mg nightly.